Type-specific neutralization of the human immunodeficiency virus with antibodies to env-encoded synthetic peptides. - sprookjes - yvandenbroek - TriplyDB

Type-specific neutralization of the human immunodeficiency virus with antibodies to env-encoded synthetic peptides.

Type-specific neutralization of the human immunodeficiency virus with antibodies to env-encoded synthetic peptides.

http://www.wikidata.org/entity/Q33560772

about

Generating neutralizing antibodies, Th1 response and MHC non restricted immunogenicity of HIV-I env and gag peptides in liposomes and ISCOMs with in-built adjuvanticity HIV-1 neutralizing antibodies: understanding nature's pathways Antigenic structure of the hepatitis C virus envelope 2 protein An epitope in hepatitis C virus core region recognized by cytotoxic T cells in mice and humans.Humoral immune response to hypervariable region 1 of the putative envelope glycoprotein (gp70) of hepatitis C virus Induction of cytotoxic T cells to a cross-reactive epitope in the hepatitis C virus nonstructural RNA polymerase-like protein Aiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidates Different Vaccine Vectors Delivering the Same Antigen Elicit CD8+ T Cell Responses with Distinct Clonotype and Epitope Specificity Structural Basis of the Cross-Reactivity of Genetically Related Human Anti-HIV-1 mAbs: Implications for Design of V3-Based Immunogens Crystal structure of a human immunodeficiency virus type 1 neutralizing antibody, 50.1, in complex with its V3 loop peptide antigen Inhibition of human immunodeficiency virus type 1 infection and syncytium formation in human cells by V3 loop synthetic peptides from gp120 SPC3, a synthetic peptide derived from the V3 domain of human immunodeficiency virus type 1 (HIV-1) gp120, inhibits HIV-1 entry into CD4+ and CD4- cells by two distinct mechanisms Synthetic multimeric peptides derived from the principal neutralization domain (V3 loop) of human immunodeficiency virus type 1 (HIV-1) gp120 bind to galactosylceramide and block HIV-1 infection in a human CD4-negative mucosal epithelial cell line Multibranched V3 peptides inhibit human immunodeficiency virus infection in human lymphocytes and macrophages Anti-V3 monoclonal antibodies display broad neutralizing activities against multiple HIV-1 subtypes Survivors Remorse: antibody-mediated protection against HIV-1.Resistance of Subtype C HIV-1 Strains to Anti-V3 Loop Antibodies.Variability of human immunodeficiency virus type 1 group O strains isolated from Cameroonian patients living in France Mutational trends in V3 loop protein sequences observed in different genetic lineages of human immunodeficiency virus type 1.The capsid gene of feline calicivirus contains linear B-cell epitopes in both variable and conserved regions 3D structure model of the principal neutralizing epitope of Minnesota HIV-1 isolate.Conformational preferences of the HIV-1 principal neutralizing determinant.Structural analysis of the HIV-1 gp120 V3 loop: application to the HIV-Haiti isolates.Human rhinovirus type 14:human immunodeficiency virus type 1 (HIV-1) V3 loop chimeras from a combinatorial library induce potent neutralizing antibody responses against HIV-1.Simian immunodeficiency virus (SIV) envelope-specific Fabs with high-level homologous neutralizing activity: recovery from a long-term-nonprogressor SIV-infected macaque.An evolutionary-network model reveals stratified interactions in the V3 loop of the HIV-1 envelope.Vertical transmission of human immunodeficiency virus is correlated with the absence of high-affinity/avidity maternal antibodies to the gp120 principal neutralizing domain.An immunodominant epitope of the human immunodeficiency virus envelope glycoprotein gp160 recognized by class I major histocompatibility complex molecule-restricted murine cytotoxic T lymphocytes.Antibodies that inhibit fusion of human immunodeficiency virus-infected cells bind a 24-amino acid sequence of the viral envelope, gp120 Nuclear magnetic resonance analysis of solution conformations in C4-V3 hybrid peptides derived from human immunodeficiency virus (HIV) type 1 gp120: relation to specificity of peptide-induced anti-HIV neutralizing antibodies Factors associated with slow disease progression in macaques immunized with an adenovirus-simian immunodeficiency virus (SIV) envelope priming-gp120 boosting regimen and challenged vaginally with SIVmac251.Group-specific, major histocompatibility complex class I-restricted cytotoxic responses to human immunodeficiency virus 1 (HIV-1) envelope proteins by cloned peripheral blood T cells from an HIV-1-infected individual.Induction of humoral immune responses following vaccination with envelope-containing, formaldehyde-treated, thermally inactivated human immunodeficiency virus type 1.Evidence that antibody-mediated neutralization of human immunodeficiency virus type 1 by sera from infected individuals is independent of coreceptor usage Cross-reactions between the cytotoxic T-lymphocyte responses of human immunodeficiency virus-infected African and European patients.Characterization of simian-human immunodeficiency virus envelope glycoprotein epitopes recognized by neutralizing antibodies from infected monkeys Mapping of epitopes exposed on intact human immunodeficiency virus type 1 (HIV-1) virions: a new strategy for studying the immunologic relatedness of HIV-1.Induction of antibodies in guinea pigs and rhesus monkeys against the human immunodeficiency virus type 1 envelope: neutralization of nonpathogenic and pathogenic primary isolate simian/human immunodeficiency virus strains.Conserved and exposed epitopes on intact, native, primary human immunodeficiency virus type 1 virions of group M.Determinants of neutralization resistance in the envelope glycoproteins of a simian-human immunodeficiency virus passaged in vivo.

P2860

Q24806405-70DE9F51-109E-4361-9E01-2F6C08807E30 Q27000480-91C24224-0734-490F-A829-63B5E479053E Q27473441-3C922BFE-5598-44B7-AB30-7BCBE96ECD61 Q27485984-50F4DDB6-51E1-4CC1-ADAD-CAC350A1716C Q27486056-8A81B1E6-C0E4-4E74-BDC6-BF354FCDEC42 Q27486239-BEFCFE97-97EB-4E2F-939A-96BB4F764632 Q27489000-D7FA8681-FDB7-4607-BEA4-747F17F27296 Q27646554-0C114BEE-F9C1-48B5-86C6-3A9B6B9EC452 Q27658173-E75923F4-F582-4F05-A211-13144084BA64 Q27731780-D63ADDD6-8B18-490D-8B38-088A0D448BF1 Q28368050-05299019-BC79-4913-9CA3-1C236A5ACC5F Q28368122-55A8D172-B3F4-4936-B387-E88E39B26B87 Q28369122-97110011-91C5-495C-AD94-29827598D2EE Q28369349-C43DECF2-9026-4105-B0A6-9630D0582E43 Q28752503-CA42A7AC-1411-4860-91F0-34E3EBF287EC Q30238730-764C3485-B8F8-4094-96EF-BDAF890AABBE Q30416200-897377FD-589C-4607-8275-F3A1F78AB2EC Q30417537-C08320EA-0191-4A45-9444-0657B425C7BC Q30420728-0ACE94E1-0144-4D06-974C-9FF5DC8B4F00 Q30769950-4EE76945-1C6F-4C2B-929F-95F1C61934ED Q30886684-3E37C4E7-DEAB-4796-BC92-B9D4A13137C7 Q31010762-390F9476-742F-48EB-A50D-9111271FC2C0 Q31112947-70BDFE93-F997-4F7C-A253-4F4735B945B5 Q32157115-B7EFAAD3-9F8D-45A0-B7CE-9EE968B6B054 Q32157141-627B10A3-69B1-4124-8AA1-FF8F0BACC548 Q33307183-111B6723-2775-4B04-9E86-A93BF28FFF06 Q33564746-D3177E28-D022-4563-8151-B2A336838D79 Q33570776-362C7B48-5AA0-414E-B9FF-5A3F2928DDB0 Q33571605-3A486FD3-D99D-4B20-A649-F94D4A9FFF66 Q33639792-3D202328-FEC9-4728-BEAE-7736CB6CCA30 Q33649657-4271E416-D3A3-4E5F-8B4D-5F70A9E89C03 Q33671780-415830F6-ED02-422A-9C0B-AF090BADBE45 Q33724169-E2787CCC-CBB6-438D-8197-F1C4DA021B51 Q33782296-38F77FBF-8E86-4CF3-8A2C-25B949FAE233 Q33782574-71CB3C99-C751-46C5-AC11-5BFA47421D93 Q33785114-3434EE91-7710-4453-9B00-998508A6271F Q33785510-92B2BBDD-20A3-4432-BA37-EA9543BFEE21 Q33794744-F3D6C112-32DC-4FA5-8F14-806F9D6E51F5 Q33809112-6A4C22E5-81F6-45BF-B3C8-BC76A295C397 Q33821658-4A22BE9D-C7E1-4A11-BDD4-12EE79DFE818

P2860

Type-specific neutralization of the human immunodeficiency virus with antibodies to env-encoded synthetic peptides.

http://www.wikidata.org/entity/Q33560772

description

1988 nî lūn-bûn

@nan

1988 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

1988 թվականի մարտին հրատարակված գիտական հոդված

@hy

1988年の論文

@ja

1988年論文

@yue

1988年論文

@zh-hant

1988年論文

@zh-hk

1988年論文

@zh-mo

1988年論文

@zh-tw

1988年论文

@wuu

name

Type-specific neutralization o ...... nv-encoded synthetic peptides.

@ast

Type-specific neutralization o ...... nv-encoded synthetic peptides.

@en

Type-specific neutralization o ...... nv-encoded synthetic peptides.

@nl

type

label

Type-specific neutralization o ...... nv-encoded synthetic peptides.

@ast

Type-specific neutralization o ...... nv-encoded synthetic peptides.

@en

Type-specific neutralization o ...... nv-encoded synthetic peptides.

@nl

prefLabel

Type-specific neutralization o ...... nv-encoded synthetic peptides.

@ast

Type-specific neutralization o ...... nv-encoded synthetic peptides.

@en

Type-specific neutralization o ...... nv-encoded synthetic peptides.

@nl

P1433

Q33560772-3FAAF3B9-90AA-4D00-85D1-F9041E1D2F34

P1476

Q33560772-68C36008-1011-4A81-96C2-C74E900F19C8

P2093

Q33560772-08C5A50C-1C70-437F-A6DA-C57C11800165

Q33560772-1F0DA2A2-3434-4478-8E26-D5D163C01BFA

Q33560772-1F80760F-39C5-4EEB-8C87-501D33F14842

Q33560772-2C1025E1-EB4D-4269-8662-321391F5871B

Q33560772-5F400E93-C9B8-4710-BF83-5F8BF25B22A4

Q33560772-842A4BD0-13B1-4019-957F-25301C5598EF

Q33560772-A5393AFB-A6B0-4FEE-B27F-924B60FDAD65

P2860

Q33560772-1281726B-0CF3-4ABE-8A18-4791516EE694

Q33560772-18923241-CFAF-4C45-AE74-2CEC94A19231

Q33560772-1A4A0D38-28CE-4FCC-A1D1-FA8FDBA8F2FD

Q33560772-1A8C0F5E-7350-42FF-915F-B2AC7A537281

Q33560772-1B757914-35E1-4888-99B1-838AA0203C85

Q33560772-20964821-F72E-48EE-AE11-0B876D903427

Q33560772-33698560-BCA1-42A1-AF2E-49BF92C88448

Q33560772-34067930-4978-4348-9209-C2E7E5F88F03

Q33560772-3E86D7A2-EFC9-4526-8115-DF24B6E980C4

Q33560772-5D442F30-B3C3-42C1-9098-54397337ACD6

P304

Q33560772-F5E91DF1-9C6F-421B-8C75-E4EC9D3F89C9

P31

Q33560772-8691A573-3C73-4459-AA72-DCC2FB9E17CB

P356

Q33560772-944342E6-1B28-48D3-ADE9-81C4DC5A8B4C

P407

Q33560772-FAE45F50-1210-4D5A-A380-9DA33BE05BD2

P433

Q33560772-5D61F3E4-69C6-44C0-B411-36AA052CB640

P478

Q33560772-60AF2D9C-6A35-4A4A-A2E4-4ECE1505660A

P50

Q33560772-3AF06E10-E459-43D2-B3C9-12B86097FECD

P577

Q33560772-51EE3DB9-16C9-4CE9-82BA-21CCA41D9E19

P5875

Q33560772-92595E83-DEEC-4B2E-B66D-48F7ADF81034

P698

Q33560772-40A7FBE6-D350-4A78-9F9B-169709855FCD

P921

Q33560772-530DDF9B-9835-46BB-99BA-B2BF27BD8F81

P932

Q33560772-5AE817EF-9837-4B7E-862A-4259A42E887D

P356

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Type-specific neutralization o ...... nv-encoded synthetic peptides.

@en

P2093

A J Langlois

http://www.w3.org/2001/XMLSchema#string

D P Bolognesi

http://www.w3.org/2001/XMLSchema#string

K J Weinhold

http://www.w3.org/2001/XMLSchema#string

M E Clark

http://www.w3.org/2001/XMLSchema#string

R R Randall

http://www.w3.org/2001/XMLSchema#string

T J Matthews

http://www.w3.org/2001/XMLSchema#string

T J Palker

http://www.w3.org/2001/XMLSchema#string

P2860

Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS)

Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications

Conformational parameters for amino acids in helical, beta-sheet, and random coil regions calculated from proteins

Complete nucleotide sequence of the AIDS virus, HTLV-III

The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus

Detection, isolation, and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS

Delineation of a region of the human immunodeficiency virus type 1 gp120 glycoprotein critical for interaction with the CD4 receptor

Binding of HTLV-III/LAV to T4+ T cells by a complex of the 110K viral protein and the T4 molecule

Functional regions of the envelope glycoprotein of human immunodeficiency virus type 1

T-lymphocyte T4 molecule behaves as the receptor for human retrovirus LAV

P304

1932-1936

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.85.6.1932

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

85

http://www.w3.org/2001/XMLSchema#string

P50

P577

1988-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

20706485

http://www.w3.org/2001/XMLSchema#string

P698

2450351

http://www.w3.org/2001/XMLSchema#string

P921

P932

279895

http://www.w3.org/2001/XMLSchema#string